These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

252 related items for PubMed ID: 33290156

  • 1. Theobromine ameliorates nonalcoholic fatty liver disease by regulating hepatic lipid metabolism via mTOR signaling pathway in vivo and in vitro.
    Wei D, Wu S, Liu J, Zhang X, Guan X, Gao L, Xu Z.
    Can J Physiol Pharmacol; 2021 Aug; 99(8):775-785. PubMed ID: 33290156
    [Abstract] [Full Text] [Related]

  • 2. Fanlian Huazhuo Formula alleviates high-fat diet-induced non-alcoholic fatty liver disease by modulating autophagy and lipid synthesis signaling pathway.
    Niu MY, Dong GT, Li Y, Luo Q, Cao L, Wang XM, Wang QW, Wang YT, Zhang Z, Zhong XW, Dai WB, Li LY.
    World J Gastroenterol; 2024 Aug 14; 30(30):3584-3608. PubMed ID: 39193572
    [Abstract] [Full Text] [Related]

  • 3. Kangtaizhi Granule Alleviated Nonalcoholic Fatty Liver Disease in High-Fat Diet-Fed Rats and HepG2 Cells via AMPK/mTOR Signaling Pathway.
    Zhang J, Du H, Shen M, Zhao Z, Ye X.
    J Immunol Res; 2020 Aug 14; 2020():3413186. PubMed ID: 32884949
    [Abstract] [Full Text] [Related]

  • 4. Maslinic acid protects against obesity-induced nonalcoholic fatty liver disease in mice through regulation of the Sirt1/AMPK signaling pathway.
    Liou CJ, Dai YW, Wang CL, Fang LW, Huang WC.
    FASEB J; 2019 Nov 14; 33(11):11791-11803. PubMed ID: 31361524
    [Abstract] [Full Text] [Related]

  • 5. Tetrahydropalmatine ameliorates hepatic steatosis in nonalcoholic fatty liver disease by switching lipid metabolism via AMPK-SREBP-1c-Sirt1 signaling axis.
    Yin X, Liu Z, Wang J.
    Phytomedicine; 2023 Oct 14; 119():155005. PubMed ID: 37562090
    [Abstract] [Full Text] [Related]

  • 6. GLP-1 analogue improves hepatic lipid accumulation by inducing autophagy via AMPK/mTOR pathway.
    He Q, Sha S, Sun L, Zhang J, Dong M.
    Biochem Biophys Res Commun; 2016 Aug 05; 476(4):196-203. PubMed ID: 27208776
    [Abstract] [Full Text] [Related]

  • 7. Oxyresveratrol ameliorates nonalcoholic fatty liver disease by regulating hepatic lipogenesis and fatty acid oxidation through liver kinase B1 and AMP-activated protein kinase.
    Lee JH, Baek SY, Jang EJ, Ku SK, Kim KM, Ki SH, Kim CE, Park KI, Kim SC, Kim YW.
    Chem Biol Interact; 2018 Jun 01; 289():68-74. PubMed ID: 29702089
    [Abstract] [Full Text] [Related]

  • 8. Procyanidin B2 ameliorates free fatty acids-induced hepatic steatosis through regulating TFEB-mediated lysosomal pathway and redox state.
    Su H, Li Y, Hu D, Xie L, Ke H, Zheng X, Chen W.
    Free Radic Biol Med; 2018 Oct 01; 126():269-286. PubMed ID: 30142454
    [Abstract] [Full Text] [Related]

  • 9. Allyl isothiocyanate ameliorates lipid accumulation and inflammation in nonalcoholic fatty liver disease via the Sirt1/AMPK and NF-κB signaling pathways.
    Li CX, Gao JG, Wan XY, Chen Y, Xu CF, Feng ZM, Zeng H, Lin YM, Ma H, Xu P, Yu CH, Li YM.
    World J Gastroenterol; 2019 Sep 14; 25(34):5120-5133. PubMed ID: 31558861
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Vine tea total flavonoids activate the AMPK/mTOR pathway to amelioration hepatic steatosis in mice fed a high-fat diet.
    Wang C, Yang F, Zeng W, Chen X, Qiu Z, Wang Q, Meng Y, Zheng G, Hu J.
    J Food Sci; 2024 May 14; 89(5):3019-3036. PubMed ID: 38517018
    [Abstract] [Full Text] [Related]

  • 13. Canagliflozin Ameliorates Nonalcoholic Fatty Liver Disease by Regulating Lipid Metabolism and Inhibiting Inflammation through Induction of Autophagy.
    Xu Z, Hu W, Wang B, Xu T, Wang J, Wei D.
    Yonsei Med J; 2022 Jul 14; 63(7):619-631. PubMed ID: 35748073
    [Abstract] [Full Text] [Related]

  • 14. Psoralea corylifolia L. extract ameliorates nonalcoholic fatty liver disease in free-fatty-acid-incubated HEPG2 cells and in high-fat diet-fed mice.
    Hong Y, Choi SI, Hong E, Kim GH.
    J Food Sci; 2020 Jul 14; 85(7):2216-2226. PubMed ID: 32579753
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. (S)YS-51, a novel isoquinoline alkaloid, attenuates obesity-associated non-alcoholic fatty liver disease in mice by suppressing lipogenesis, inflammation and coagulation.
    Park EJ, Kim YM, Kim HJ, Jang SY, Oh MH, Lee DH, Chang KC.
    Eur J Pharmacol; 2016 Oct 05; 788():200-209. PubMed ID: 27343380
    [Abstract] [Full Text] [Related]

  • 18. Thrombospondin 1 improves hepatic steatosis in diet-induced insulin-resistant mice and is associated with hepatic fat content in humans.
    Bai J, Xia M, Xue Y, Ma F, Cui A, Sun Y, Han Y, Xu X, Zhang F, Hu Z, Liu Z, Liu Y, Cai G, Su W, Sun X, Wu H, Yan H, Chang X, Hu X, Bian H, Xia P, Gao J, Li Y, Gao X.
    EBioMedicine; 2020 Jul 05; 57():102849. PubMed ID: 32580141
    [Abstract] [Full Text] [Related]

  • 19. Fisetin Protects Against Hepatic Steatosis Through Regulation of the Sirt1/AMPK and Fatty Acid β-Oxidation Signaling Pathway in High-Fat Diet-Induced Obese Mice.
    Liou CJ, Wei CH, Chen YL, Cheng CY, Wang CL, Huang WC.
    Cell Physiol Biochem; 2018 Jul 05; 49(5):1870-1884. PubMed ID: 30235452
    [Abstract] [Full Text] [Related]

  • 20. LB100 ameliorates nonalcoholic fatty liver disease via the AMPK/Sirt1 pathway.
    Chen XY, Cai CZ, Yu ML, Feng ZM, Zhang YW, Liu PH, Zeng H, Yu CH.
    World J Gastroenterol; 2019 Dec 07; 25(45):6607-6618. PubMed ID: 31832001
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.